A new oral medication for type 1 diabetes, sotagliflozin, has been developed by  Lexicon Pharmaceuticals; the company plans to file marketing applications worldwide in the first half of 2018. In trials, patients taking sotagliflozin in addition to insulin showed significant improvements in glucose control, a drop in systolic and diastolic blood pressure and weight loss. If approved, the drug will be the first oral pill for type 1 in the market. Read more